Benzazepine derivative for vasopressin receptor disease treatment
Summary
Benzazepine derivative for vasopressin receptor disease treatment
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
New-type benzazepine fused ring derivative
Grant US12600729B2 Kind: B2 Apr 14, 2026
Assignee
SHANGHAI JEYOU PHARMACEUTICAL CO., LTD.
Inventors
Hongfu Lu, Dezhi Qiu, Jianbiao Peng
Abstract
A benzazepine fused ring derivative as represented by formula (I) or a pharmaceutically acceptable salt thereof, and the use of a compound in the diagnosis, prevention and/or treatment of diseases related to vasopressin receptors.
CPC Classifications
C07D 487/04 A61P 13/12 A61K 31/55
Filing Date
2022-03-04
Application No.
18547513
Claims
15
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.